GaryBlickMD

Internal Medicine • Stratford, CT

HIV/AIDS Medicine, Preventive Medicine, STD Medicine

Chief Medical Officer, Health Care Advocates International

Join to view full profile

Dr. Blick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Blick's full profile

Already have an account?

Office
3115 Main Street
Ste 2
Stratford, CT 06614
Phone+1 203-345-0404

Fax+1 203-908-4110
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1984 - 1985
University of Miami Leonard M. Miller School of MedicineClass of 1984

Certifications & Licensure

NY State Medical License 1985 - 2025
CT State Medical License 1986 - 2024
American Academy of HIV MedicineHIV SPECIALIST

Clinical Trials

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults Start of enrollment: 1999 May 01
Completed
Phase 1
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs Start of enrollment: 2000 Aug 01
Unknown status
Phase 3
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 2
Safety and Efficacy Study of Switching From Epzicom to Truvada Start of enrollment: 2008 Jul 01
Completed
Phase 4
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Start of enrollment: 2010 Nov 01
Completed
Phase 1, Phase 2
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Start of enrollment: 2012 Apr 18
Completed
Phase 3
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART Start of enrollment: 2014 Aug 01
Completed
Phase 1, Phase 2
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Start of enrollment: 2014 Dec 01
Completed
Phase 3
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Start of enrollment: 2016 Mar 10
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phas...
Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C> ;Lancet HIV. 2015 Apr
17 citations
Exploring Social Networking Technologies as Tools for HIV Prevention for Men Who Have Sex With Men.
Jorge Ramallo, Thomas Kidder, Tashuna Albritton, Gary Blick, John E. Pachankis, Valen Grandelski, Trace Kershaw> ;AIDS Education and Prevention. 2015 Aug 1
254 citations
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
, , , , , , , , , , , , , , , , , , , , , , , > ;JAMA. 2015 Mar 24
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nicho...> ;J Infect Dis. 2014 Aug 01
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label ...
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S> ;Lancet. 2014 Jun 28
14 citations
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Joseph J. Eron, J. Lalezari, Jihad Slim, Joseph Gathe, Peter Ruane, Chia Wang, Richard Elion, Gary Blick, Amit Khatri, Yiran B Hu, Krystal Gibbons, Linda M Fredrick, M...> ;Journal of the International AIDS Society. 2014 Nov 2
55 citations
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Bisher Akil, Gary Blick, Debbie Hagins, Moti Ramgopal, Gary Richmond, Rafik M Samuel, Naomi Givens, Cindy Vavro, Ivy Song, Brian Wynne, Mounir Ait-Khaled> ;Antiviral Therapy. 2014 Apr 1
Testosterone Replacement Therapy in Men with Hypogonadism and HIV/AIDS: Results from the TRiUS Registry
Mohit Khera, Martin M Miner, Gary Blick, Rajib K Bhattacharya> ;Taylor & Francis Online.
9 citations
Optimal Diagnostic Measures and Thresholds for Hypogonadism in Men With HIV/AIDS: Comparison Between 2 Transdermal Testosterone Replacement Therapy Gels
Gary Blick> ;Postgraduate Medicine. 2013 Mar 1
20 citations
12-month observation of testosterone replacement effectiveness in a general population of men.
Martin Miner, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Mohit Khera> ;Postgraduate Medicine. 2013 Mar 1
76 citations
Patient monitoring and follow-up in lentiviral clinical trials
Gerard J. McGarrity, Gloria Hoyah, April Winemiller, Kris Andre, David Stein, Gary Blick, Richard N. Greenberg, Clifford Kinder, Andrew R. Zolopa, Gwen Binder-Scholl, ...> ;The Journal of Gene Medicine. 2013 Feb 1
24 citations
Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Rajib K. Bhattacharya, Mohit Khera, Gary Blick, Harvey Kushner, Martin Miner> ;Clinical Interventions in Aging. 2012 Aug 24
11 citations
Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES).
Benjamin Bassichis, Gary Blick, Marcus A. Conant, David Condoluci, Michael I. Echavez, Joseph A. Eviatar, Michael H. Gold, Tiffani Hamilton, C. William Hanke, Gail Hum...> ;Dermatologic Surgery. 2012 Jul 1
25 citations
Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Gary Blick, Mohit Khera, Rajib K. Bhattacharya, Dat Nguyen, Harvey Kushner, Martin Miner> ;Pain Medicine. 2012 May 1
Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Blick, G.,Greiger-Zanlungo, P.,Gretz, S.,Han, J.,Dupree, D.,Garton, T.,Yau, L. H.,Wine, B. C.,Pakes, G. E.> ;Int J STD AIDS. 2012 May 15
37 citations
The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin Miner> ;The Aging Male. 2012 Feb 4
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhib...
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL> ;Lancet Infect Dis. 2012 Jan
51 citations
Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)
Rajib K. Bhattacharya, Mohit Khera, Gary Blick, Harvey Kushner, Dat Nguyen, Martin Miner> ;BMC Endocrine Disorders. 2011 Nov 1
41 citations
Improved Sexual Function with Testosterone Replacement Therapy in Hypogonadal Men: Real-World Data from the Testim Registry in the United States (TRiUS)
Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin Miner> ;The Journal of Sexual Medicine. 2011 Nov 1
56 citations
Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin Miner> ;The Journal of Urology. 2011 Sep 1
17 citations
Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency.
Martin Miner, Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner> ;Postgraduate Medicine. 2011 May 1
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS> ;AIDS. 2009 Jul 31
21 citations
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
Calvin J. Cohen, Daniel S Berger, Gary Blick, Howard Grossman, Dushyantha Jayaweera, P. Shalit, Melanie A. Thompson, Monika Peeters, Marie-Pierre de Béthune, Ellen Voo...> ;AIDS. 2009 Jan 28
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous ...> ;N Engl J Med. 2008 Oct 02
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead ...> ;N Engl J Med. 2008 Oct 02
Join now to see all

Press Mentions

COVID-19 Increases Urgency for Legislature to Pass Medical Aid-in-Dying LawFebruary 26th, 2021
Front Line Hero of COVID-19 Crisis, LGBTQ Advocate HonoredAugust 30th, 2020
Renown HIV Specialist Dr. Gary Blick Joins Immune Therapeutics Advisory BoardAugust 23rd, 2018
Join now to see all

Professional Memberships

American Medical Association - AMA
Member
American Academy of HIV Medicine
Member
International AIDS Society
Member
HIV Medical Association
Member
International Association of Providers of AIDS Care
Member
CT State Medical Society
Member
Fairfield County Medical Association
Member